Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 5, 1998, Pages 353-359

  Phillips, G J ^a   Davies, J G ^a   Olliff, C J ^a   Kingswood, C ^b   Street, M ^b  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPIROME; POLYACRYLONITRILE; POLYAMIDE;

ARTICLE; CRITICAL ILLNESS; DIALYSIS MEMBRANE; DOSE CALCULATION; DRUG CLEARANCE; FLOW RATE; HEMODIALYSIS; HEMOFILTRATION; HOLLOW FIBER MEMBRANE; INFECTION; ULTRAFILTRATION;

EID: 0031650701     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00169.x     Document Type: Article

References (16)

1. Goldstein EJC, Citron DM. (1985) Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and non-tolerant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 28, 160-162.
2. Jones RN, Pfaller MA, Allen SD, Gerlach EH, Fuchs PC, Aldridge KE. (1991) Antimicrobial activity of cefpirome: an update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centres. Diagnostic Microbiology and Infectious Disease, 14, 361-364.
3. Kavi J, Andrews JM, Ashby JP, Hillman G, Wise R. (1988) Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. Journal of Antimicrobial Chemotherapy, 22, 911-916.
4. Meyer BH, Muller FO, Luus HG, Drees B, Rothig HJ, Badian M, Eckert HG. (1992) Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects. Journal of Antimicrobial Chemotherapy, 29(Suppl. A), 63-70.
5. Verho M, Maass L, Malerczyk V, Grotsch H. (1987) Renal tolerance of cefpirome (HR-810), a new cephalosporin antibiotic. Infection, 15, 215-219.
6. Uihlein M, Klesel N, Seegar K. (1988) Determination of cefpirome (HR-810) in serum and urine. Infection, 16, 135-140.
7. Bickley SK. (1988) Drug dosing during continuous arteriovenous haemofiltration. Clinical Pharmacology, 7, 198-206.
8. Lau AH, Kronfol NO. (1994) Determinants of drug removal by continuous haemofiltration. International Journal of Artificial Organs, 17, 373-378.
9. Lameire N, Malerczyk V, Drees B, Lehr K, Rosenkranz B. (1992) Single-dose pharmacokinetics of cefpirome in patients with renal impairment. Clinical Pharmacology and Therapeutics, 52, 24-30.
10. Veys N, Lameire N, Malerczyk DM, Lehr KH, Rosenkranz B, Ringoir S. (1993) Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and patients treated by continuous ambulatory peritoneal dialysis. Clinical Pharmacology and Therapeutics, 54, 395-401.
11. Vincent HH, Vos MC, Akcahuseyin E, Goessens WHF, Van Duyl WA, Schlekamp MA. (1993) Drug clearance by continuous haemodiafiltration. Blood Purification, 11, 99-107.
12. Golper T. (1991) Drug removal during continuous hemofiltration or hemodialysis. Tn: Sieberth HG, Mann H, Stummvoll HK, eds. Continuous Hemofiltration. Contributions to Nephrology. Basel: Karger (93), 110-116.
13. Reetze-Bonorden P, Bohler J, Keller E. (1993) Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clinical Pharmacokinetics, 24, 362-379.
14. Davies SP, Kox WJ, Brown EA. (1991) Clearance studies in patients with acute renal failure treated by continuous arteriovenous haemodialysis. In: Sieberth HG, Mann H, Stummvoll HK, eds. Continuous Hemofiltration. Contributions to Nephrology. Basel: Karger (93), 117-119.
15. Sprenger KGB, Stephen H, Kratz W, Huber K, Franz HE. (1985) Optimising of haemodiafiltration with modern membranes. Contributions to Nephrology, 46, 43-60.
16. British Medical Association and the Royal Pharmaceutical Society of Great Britain. (1997) British National Formulary 34. London: Pharmaceutical Press, 577-579.